Wir verwenden standardmäßig essenzielle Cookies (Anmeldung, deine gespeicherten Ziele/Stacks). Mit deiner Erlaubnis aktivieren wir außerdem datenschutzfreundliche Analytik (Vercel Web Analytics, anonyme Ladezeit-Metriken) und Fehler-Replay-Diagnostik (Sentry — DOM-Snapshots nur, wenn ein Fehler auftritt), damit wir Bugs schneller beheben können. Mehr über Cookies erfahren
Bco5.0
Black Cohosh – Forschung
Hilft wahrscheinlich
50 begutachtete Studien
Was die Evidenz sagt
Hilft wahrscheinlich
Black Cohosh scheint in 7 von 10 Studien mit messbaren Effekten zu helfen — die Evidenz tendiert klar ins Positive.
Die meiste Evidenz stammt aus hochwertigen Meta-Analysen und randomisierten Studien, veröffentlicht 2005–2026 mit einer typischen Studiengröße von 304 Teilnehmenden.
Basierend auf 50 Studien · 7 Meta-Analysen · 14 RCTs · 67,925 Teilnehmende insgesamt
Konfidenz
Hohe Konfidenz
Was die Studien gefunden haben
7geholfen3unklar· 40 weitere ohne bewertete Effektdaten
Nach Outcome
Menopause & vasomotor symptomsMäßige, inkonsistente Reduktion von Hitzewallungen und nächtlichem Schwitzen · 4-8 weeks · Verändert die Hormonspiegel nicht; nicht-östrogene Wirkung · 4-8 weeks
Hilft wahrscheinlich45 Studien
Safety profile
Überwiegend Mechanismus / Beobachtung15 Studien
Therapeutic & clinical
Hilft vermutlich9 Studien
Liver health
Überwiegend Mechanismus / Beobachtung5 Studien
Depression & mood
Hilft vermutlich4 Studien
Anxiety & stress
Überwiegend Mechanismus / Beobachtung3 Studien
Sleep & insomnia
Zu wenige bewertete Studien2 Studien
Fertility & reproductive
Zu wenige bewertete Studien1 Studie
Bone health
Zu wenige bewertete Studien1 Studie
Cholesterol & lipids
Zu wenige bewertete Studien1 Studie
In Zahlen
Aus 33 Studien mit messbaren Effekten gezogen
Wahrscheinlich echte Effekte
25%
über Studien hinweg
Untersuchte Personen
68k
typische Studie: 304 Personen
Stärkste Designs
21
7 gepoolt, 14 randomisiert
Zeigte Nutzen
70%
7/10 Studien
Wie lange Studien liefen
1–3 Monate
2
3+ Monate
4
Untersuchte Populationen
Menopausal women7
Women with menopausal symptoms2
Women with climacteric complaints2
Patients with menopausal symptoms1
Aktives Forschungsgebiet
22 Studien in den letzten 5 Jahren · Neueste Meta-Analyse: 2024
200520152026
1Systematische Übersichtn=2,027 · very large study2012
There is currently insufficient evidence to support the use of black cohosh for menopausal symptoms.
Leach MJ, Moore V · Cochrane Database of Systematic Reviews (2012)
Sixteen RCTs recruiting 2027 perimenopausal or postmenopausal women were identified
No significant difference between black cohosh and placebo in frequency of hot flushes or menopausal symptom scores
Evidence on the safety of black cohosh was inconclusive owing to poor reporting
2Anxiety symptomsMeta-AnalyseCited 5×n=2,310 · very large study2023
This study provides updated evidence regarding the potentially beneficial effects of black cohosh extracts for relieving menopausal symptoms in menopausal women.
Sadahiro R et al. · Menopause (New York, N.Y.) (2023)
Kein klarer Effekt
← SchlechterKein EffektBesser →
Could be chance
However, black cohosh did not significantly improve anxiety (Hedges' g = 0.194, 95% CI = -0.296 to 0.684, P = 0.438) or depressive symptoms (Hedges' g = 0.406, 95% CI = -0.121 to 0.932, P = 0.131).
The dropout rate for black cohosh products was similar to that for placebo (odds ratio = 0.911, 95% CI = 0.660 to 1.256, P = 0.568).
This study provides updated evidence regarding the potentially beneficial effects of black cohosh extracts for relieving menopausal symptoms in menopausal women.
3Meta-AnalyseCited 21×n=43,759 · very large study2021
With its good safety profile in general and at estrogen-sensitive organs, iCR as a non-hormonal herbal therapy can also be used in patients with hormone-dependent diseases who suffer from iatrogenic climacteric symptoms.
Castelo-Branco C et al. · Climacteric : the journal of the International Menopause Society (2021)
Effect sizes were larger when higher dosages of iCR as monotherapy or in combination with St.
The clinical data did not reveal any evidence of hepatotoxicity.
Hormone levels remained unchanged and estrogen-sensitive tissues (e.g. breast, endometrium) were unaffected by iCR treatment.
6Serum estradiol levelsSystematische ÜbersichtCited 2×n=745 · large study2020
The limited evidence so far indicates that BCE could efficiently improve perimenopausal symptoms cause by low estrogen status of the patients recieved GnRHa treatment after surgery for endometriosis, but does not alter hormone levels of patients.
Peng J et al. · Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences (2020)
Kein klarer Effekt
← SchlechterKein EffektBesser →
Meta-analysis results showed that the addition of BCE did not alter hormone levels of patients, including serum estradiol levels [ MD=1.24, 95% CI(-4.58, 7.08), P>0.05] and luteinizing hormone levels [ MD=-0.02, 95% CI(-0.15, 0.11), P>0.05].
BCE affected Kupperman's menopausal index (KMI) score 12 weeks after the surgery [ MD=-11.50, 95% CI(-20.09, -2.90), P < 0.01] and KMI score 24 weeks after the surgery [ MD=-23.68, 95% CI(-39.66, -7.69), P < 0.01].
The limited evidence so far indicates that BCE could efficiently improve perimenopausal symptoms cause by low estrogen status of the patients recieved GnRHa treatment after surgery for endometriosis, but does not alter hormone levels of patients.
7Aspartate aminotransferase levelsMeta-AnalyseCited 54×n=517 · large study2011
The results of this meta-analysis of five randomized, double-blind, and controlled clinical trials showed no evidence that iCR has any adverse effect on liver function.
Naser B et al. · Menopause (New York, N.Y.) (2011)
Kein klarer Effekt
← SchlechterKein EffektBesser →
Could be chance
The overall fixed effect ± SEM was 0.055 ± 0.062 (P=0.37) for aspartate aminotransferase and 0.063 ± 0.062 (P=0.31) for alanine aminotransferase.
The results of this meta-analysis of five randomized, double-blind, and controlled clinical trials showed no evidence that iCR has any adverse effect on liver function.
This article discusses the medicinal and traditional histories of various Cimicifuga species.
Fatima S et al. · Fitoterapia (2024)
This article discusses the medicinal and traditional histories of various Cimicifuga species.
Because quality control and safety assessments of Cimicifuga species are currently lacking, only a limited portion of the plant may be used as medication.
The majority of current research focuses on triterpene glycosides.
After using a variety of phytoestrogens in different forms indicators of urogenital atrophy and urinary disorders improved and women's sexual function improved after treatment.
Abdi F et al. · European journal of obstetrics, gynecology, and reproductive biology (2021)
After using a variety of phytoestrogens in different forms indicators of urogenital atrophy and urinary disorders improved and women's sexual function improved after treatment.
The use of phytoestrogens as a safe, low-risk compared to hormone therapy and almost accessible method for women can relieve urogenital symptoms and promote the sexual satisfaction and quality of life.
However, well-designed larger clinical trials are needed before these herbs can be recommended and to further assess their psycho-oncologic relevance.
Yeung KS et al. · Phytotherapy research : PTR (2018)
Overall, 45% of studies reported positive findings with fewer adverse effects compared with conventional medications.
Based on available data, black cohosh, chamomile, chasteberry, lavender, passionflower, and saffron appear useful in mitigating anxiety or depression with favorable risk-benefit profiles compared to standard treatments.
These may benefit cancer patients by minimizing medication load and accompanying side effects.
In this systematic review we present information relating to the effectiveness and safety of the following interventions: agnus castus, antidepressants, black cohosh, clonidine, oestrogens, phyto-oestrogens, progestogens, testosterone, and tibolone.
Burbos N et al. · BMJ clinical evidence (2011)
In this systematic review we present information relating to the effectiveness and safety of the following interventions: agnus castus, antidepressants, black cohosh, clonidine, oestrogens, phyto-oestrogens, progestogens, testosterone, and tibolone.
Further research warranted to confirm findings
14Systematische ÜbersichtCited 11×2019
In conclusion, with its positive benefit-risk profile, iCR/iCR + HP may offer a safe non-hormonal therapeutic option for breast cancer survivors receiving endocrine therapy.
Ruan X et al. · Climacteric : the journal of the International Menopause Society (2019)
After breast cancer, even if receiving tamoxifen, patients using iCR/iCR + HP had significantly increased recurrence-free survival rates compared to non-users.
These results are substantiated by experimental data demonstrating antiproliferative and anti-invasive effects of iCR in breast cancer cells and enhancement of the antineoplastic effects of tamoxifen.
There are no known clinical interactions for iCR and HP with endocrine therapies.
The decision to use hormone therapy depends on clinical presentation, a thorough evaluation of the risks and benefits, and an informed discussion with the patient.
Hill DA et al. · American family physician (2016)
One systematic review suggests modest improvement in hot flashes and vaginal dryness with soy products, and small studies suggest that clinical hypnosis significantly reduces hot flashes.
Patients with genitourinary syndrome of menopause may benefit from vaginal estrogen, nonhormonal vaginal moisturizers, or ospemifene (the only nonhormonal treatment approved by the U.S.
Food and Drug Administration for dyspareunia due to menopausal atrophy).
16Systematische ÜbersichtCited 26×2012
CR monotherapy as well as HP and Agnus castus showed no better effect than placebo.
Laakmann E et al. · Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology (2012)
CR monotherapy as well as HP and Agnus castus showed no better effect than placebo.
The combination of CR with HP demonstrated a positive effect on climacteric complaints.
17Efficacy for menopausal symptomsSystematische ÜbersichtCited 73×n=1,112 · large study2008
The efficacy of black cohosh as a treatment for menopausal symptoms is uncertain and further rigorous trials seem warranted.
Borrelli F et al. · Pharmacological research (2008)
Trials were excluded if they did not focus on menopausal problems, they included women suffering medically induced menopause, they did not use black cohosh monopreparations, or they did not use placebo or a standard drug treatment for the control group.
Six studies with a total of 1112 peri- and post-menopausal women met our inclusion criteria.
The evidence from these RCTs does not consistently demonstrate an effect of black cohosh on menopausal symptoms; a beneficial effect of black cohosh on peri-menopausal women cannot be excluded.
20Hot flash frequency and menopausal symptomsMeta-Analysen=1,787 · large study2024
A comprehensive 2024 meta-analysis updating the evidence base for black cohosh in menopausal symptom management, directly informing clinical recommendations.
Mehrpooya M et al. · Phytomedicine (2024)
Black cohosh significantly reduced hot flash frequency versus placebo across pooled RCTs
Kupperman Index scores improved significantly in women receiving black cohosh extracts
Liver-related adverse events were not significantly more frequent than placebo